- 1 Unpacking sources of transmission in HIV prevention trials with deep-sequence pathogen data
- 2 BCPP/ Ya Tsie study

- 4 Lerato E. Magosi<sup>1,2\*</sup>, Eric Tchetgen Tchetgen<sup>3</sup>, Vlad Novitsky<sup>4,5</sup>, Molly Pretorius Holme<sup>4</sup>, Janet
- 5 Moore<sup>6</sup>, Pam Bachanas<sup>6</sup>, Refeletswe Lebelonyane<sup>7</sup>, Christophe Fraser<sup>8</sup>, Sikhulile Moyo<sup>5</sup>,
- 6 Kathleen E. Hurwitz<sup>9</sup>, Tendani Gaolathe<sup>5</sup>, Ravi Goyal<sup>10</sup>, Joseph Makhema<sup>5</sup>, Shahin Lockman<sup>4,5,11†</sup>,
- 7 Max Essex<sup>4,5†</sup>, Victor De Gruttola<sup>9†</sup>, & Marc Lipsitch<sup>1†\*</sup>
- 8
- 9 1. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan
- 10 School of Public Health, Harvard University, Boston, USA
- 11 2. Wellcome Sanger Institute, Cambridge, United Kingdom
- 12 3. Department of Statistics, The Wharton School, University of Pennsylvania, Philadelphia, USA
- 13 4. Harvard T.H. Chan School of Public Health AIDS Initiative, Department of Immunology and
- 14 Infectious Disease, Harvard T.H. Chan School of Public Health, Harvard University, Boston, USA
- 15 5. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
- 16 6. Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, USA
- 17 7. Ministry of Health, Republic of Botswana, Gaborone, Botswana
- 18 8. Oxford Big Data Institute, Li Ka Shing Center for Health Information and Discovery, Nuffield
- 19 Department of Medicine, Old Road Campus, University of Oxford, Oxford, UK
- 20 9. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University,
- 21 Boston, USA
- 10. Division of Infectious Diseases and Global Public Health, University of California San Diego,
- 23 La Jolla CA, USA
- 24 11. Brigham and Women's Hospital, Division of Infectious Diseases, Boston, USA
- 25
- 26 <sup>+</sup>These authors contributed equally to this work and are co-senior authors
- 27
- 28 \*Corresponding author. Email: <u>Imagosi@hsph.harvard.edu</u> (Lerato E. Magosi, DPhil);
- 29 mlipsitc@hsph.harvard.edu (Marc Lipsitch, DPhil)

### 30 Abstract

31 To develop effective HIV prevention strategies that can guide public health policy it is important 32 to identify the main sources of infection in HIV prevention studies. Accordingly, we devised a 33 statistical approach that leverages deep- (or next generation) sequenced pathogen data to estimate the relative contribution of different sources of infection in community-randomized 34 35 trials of infectious disease prevention. We applied this approach to the Botswana Combination Prevention Project (BCPP) and estimated that 90% [95% Confidence Interval (CI): 81 – 93] of 36 37 new infections that occurred in individuals in communities that received combination 38 prevention (including universal HIV test-and-treat) originated from individuals residing in 39 communities outside of the trial area. We estimate that the relative impact of the intervention 40 was greater in rural geographically isolated communities with limited opportunity for imported infections compared to communities neighboring major urban centers. Treating people with 41 HIV limits the spread of infection to uninfected individuals; accordingly, counterfactual 42 43 modeling scenarios estimated that a nationwide application of the intervention could have 44 reduced transmissions to recipients in trial communities by 59% [3 – 87], much higher than the 45 observed 30% reduction. Our results suggest that the impact of the BCPP trial intervention was 46 substantially limited by sources of transmission outside the trial area, and that the impact of the intervention could be considerably larger if applied nationally. We recommend that studies 47 48 of infectious disease prevention consider the impact of sources of transmission beyond the 49 reach of the intervention when designing and evaluating interventions to inform public health 50 programs.

51

- 2 -

## 53 Introduction

54

55	Why did the landmark community-randomized universal HIV test-and-treat trials in sub-
56	Saharan Africa - BCPP/ Ya Tsie [1], HPTN 071/ PopART [2], SEARCH [3] and ANRS 12249/TasP [4]
57	- show variable reductions in the occurrence of new HIV infections in trial communities that
58	received the intervention compared to control communities (0% – 30%) despite substantial
59	gains in viral suppression [5]? This is one of the most important questions in the HIV policy
60	world today because HIV 'test-and-treat' was thought to hold great potential to bring the HIV
61	epidemic under control in the absence of a successful vaccine or functional cure. Some of the
62	variation in the incidence reductions observed is thought to be due to a change in national HIV
63	treatment guidelines to universal treatment part-way through the trials effectively reducing the
64	difference between intervention and control communities. Another complementary hypothesis
65	is that HIV transmissions to residents of intervention communities from individuals in non-
66	intervention communities in the trial (control communities) and from communities not taking
67	part in the trial (non-trial communities) limited the size of effect observed in the trials, but it is
68	unknown to what degree. A large dilution of the intervention effect in the trials by transmission
69	from non-intervention communities could suggest a larger impact of the intervention than
70	originally envisaged [6-8].
71	

We test this hypothesis in one of the four trials, the Botswana Combination Prevention Project.
Specifically, we developed a statistical modeling approach that uses directed sexual contacts
inferred from deep-sequenced HIV virus to estimate the relative extent to which transmissions

- 4 -

75	in trial communities occurred from individuals in the same community; different communities
76	in the same trial arm; different communities in the opposite trial arm; and non-trial
77	communities. In addition, to estimate what the impact of a nationwide intervention would have
78	been on recipients in trial communities, we apply our statistical approach in "counterfactual"
79	modeling scenarios that estimate the relative contribution of the different sources of infection
80	mentioned above in the presence and absence of the intervention. Note that in a nationwide
81	intervention all communities nationally would receive combination prevention (including
82	universal HIV test-and-treat).
83	
84	

### 86 Materials and Methods

87

### 88 BCPP Study Description and Data

89 BCPP study description. The Botswana Combination Prevention Project (BCPP, also known as 90 the Ya Tsie trial) was a pair-matched community-randomized trial to evaluate the effect of 91 universal HIV testing and treatment on HIV incidence reduction. The trial was conducted in 30 92 rural and peri-urban communities across Botswana from 2013-2018 [1]. Trial participants were 93 adults aged 16-64 years and the average population size eligible to participate in each trial 94 community was 3,820 people. Communities were matched into 15 pairs based on three criteria: 95 geographical proximity to major urban areas (Gaborone city, Palapye and Francistown city), 96 population size and age structure, and access to health services; then within each pair, communities were randomized into the intervention and control arms of the trial. The 15 97 98 intervention communities in the trial received expanded access to universal HIV testing (with 99 attempt to test all willing adult residents who did not have documented positive HIV status), 100 strengthened linkage-to-care for early treatment, and expanded treatment availability. After a 101 period of community sensitization through door-to-door canvassing, community leadership 102 engagement and public loudspeaker announcements, mobile and home-based HIV testing 103 campaigns were conducted within each intervention community over approximately two 104 consecutive months [9]. Routine testing in intervention community health facilities was 105 reinforced to diagnose all people with HIV and avail them early treatment. An additional effort 106 was made to offer HIV testing to men and youth where they work and socialize, for example: at 107 bars and community football (soccer) matches. To strengthen linkage-to-care, people with HIV

- 6 -

108 who were not on treatment were assisted to schedule an appointment at a local clinic, 109 provided text alerts prior to the appointment and followed-up to re-schedule in the case of a 110 missed appointment. Access to services for safe male circumcision and prevention of mother-111 to-child transmission was also expanded in intervention communities. By comparison, control 112 communities received the standard-of-care, which before 2016 meant that people with HIV 113 gualified to start antiretroviral treatment when their CD4 cell count was below 350 cells per 114 microliter. Beginning June 2016, the national HIV treatment policy was changed to universal 115 treatment meaning that immediate antiretroviral treatment was now available in both arms of 116 the BCPP trial. To evaluate HIV incidence reduction, an HIV incidence follow-up cohort was established through a baseline household survey of a random sample of 20% of households in 117 118 each trial community. Annual household surveys with retesting for HIV (in persons who were 119 HIV-negative) were then conducted in the same 20% household sample in all 30 communities 120 during the trial. The BCPP trial comprised 7.6% (175,664) of the national population and 121 showed a 30% reduction in the occurrence of new HIV infections in intervention communities 122 compared to control communities over an average of 29 months [1]. In addition, the BCPP trial 123 conducted an end-of-study survey of 100% of households in 3 intervention communities and 3 124 control communities to assess progress on the 90-90-90 UNAIDS targets. Trial participants with HIV were invited to provide a sample for viral phylogenetic analysis. This included all people 125 126 with HIV from (1) the baseline household survey, (2) annual household surveys, (3) end-of-study 127 survey, as well as (4) all people with HIV (but not yet on ART) who were referred for treatment 128 during community-wide testing and counseling campaigns, (5) all people with HIV that later

- 7 -

presented at health care facilities in intervention communities and (6) all people with HIV who
were already receiving HIV care at health facilities in intervention communities.

131

132 Deep-sequence phylogenetics data. Near full-length genome sequences were obtained using 133 predominantly proviral DNA (as the majority of study participants were virally suppressed on 134 ART) or RNA. The HIV-1 viral consensus whole genomes of individuals that met minimum 135 criteria for inclusion in phylogenetic analyses were ones that had fewer than 30% of bases 136 missing beyond the first 1,000 nucleotides [10]. To efficiently use computational resources, viral 137 consensus whole genomes were used to identify groups (or clusters) of trial participants with 138 genetically similar HIV-1 infections as a filtering step to exclude distantly related sequences 139 from deep-sequence phylogenetic analysis [10]. A detailed description of the deep-sequence 140 phylogenetic analysis is published in [10]. Briefly, we performed ancestral host-state reconstruction with the phyloscanner software [11, 12] to identify pairs of trial participants 141 142 with genetically similar HIV-1 infections and the probable direction of transmission between 143 them (female-to-male or male-to-female). For brevity, we refer to the directed opposite-sex 144 transmission pairs as source-recipient pairs. For each identified transmission pair there was 145 accompanying metadata on the names of the communities in which the source and recipient 146 partners reside and the randomization-condition to which their communities were assigned. 147 148 Pairwise drive distance data. Pairwise drive distances between ordered pairs of 488

149 communities in the 2011 Botswana population and housing census were successfully sourced

150 from the google distance matrix application programming interface (API) with the mapsapi

- 8 -

151	package v0.5.0 in R v4.1.1 [13]. The 488 census communities included all 30 communities in the
152	BCPP trial. Therefore, of the possible 488 x 488 ordered community pairs between the 488
153	census communities we sourced 488 x 30 ordered community pairs that had any of the 488
154	census communities as a source (origin) community and any of the 30 trial communities as a
155	recipient (destination) community.
156	
157	Population-size and HIV prevalence estimates. Population-size estimates of 488 communities in
158	the 2011 Botswana population and housing census were sourced from [14], and district-level
159	HIV prevalence estimates were obtained from the 2013 Botswana AIDS Impact Survey (BAIS
160	2013) [15].
161	
162	Estimating Transmissions to Recipients in BCPP Trial Communities
162 163	Estimating Transmissions to Recipients in BCPP Trial Communities
162 163 164	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different
162 163 164 165	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events
162 163 164 165 166	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we
162 163 164 165 166 167	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we statistically modeled the risk of transmission between trial communities using a negative-
162 163 164 165 166 167 168	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we statistically modeled the risk of transmission between trial communities using a negative- binomial regression framework; with the inferred transmission events as the response variable
162 163 164 165 166 167 168 169	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we statistically modeled the risk of transmission between trial communities using a negative- binomial regression framework; with the inferred transmission events as the response variable and the following variables as predictors: (1) the pairwise drive distance separating the source
162 163 164 165 166 167 168 169 170	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we statistically modeled the risk of transmission between trial communities using a negative- binomial regression framework; with the inferred transmission events as the response variable and the following variables as predictors: (1) the pairwise drive distance separating the source and recipient communities, (2) whether the source community was randomized to receive the
162 163 164 165 166 167 168 169 170 171	Estimating Transmissions to Recipients in BCPP Trial Communities To estimate transmissions that occurred to recipients in trial communities from different sources of infection nationally, we first inferred directed (opposite-sex) transmission events between the 30 BCPP trial communities using deep-sequence phylogenetics. Then we statistically modeled the risk of transmission between trial communities using a negative- binomial regression framework; with the inferred transmission events as the response variable and the following variables as predictors: (1) the pairwise drive distance separating the source and recipient communities, (2) whether the source community was randomized to receive the intervention, and (3) whether the source community and the recipient community were the

173	that we used the pairwise drive distances between the 488 communities in the 2011 Botswana
174	population and housing census as input to the model of the risk of transmission between trial
175	communities to predict the risk of transmission (expected probability of viral genetic-linkage
176	had the cases been sequenced) between communities nationally. Finally, to estimate the
177	number of transmissions into trial communities from all communities nationally, estimates of
178	the risk of transmission to recipients in trial communities from communities nationally were
179	combined with population-size estimates from the 2011 Botswana population and housing
180	census [14] and district-level HIV prevalence estimates from the 2013 Botswana AIDS Impact
181	Survey (BAIS 2013) [15]. The supplementary appendix provides a detailed account of the
182	statistical approach used to estimate the relative contribution of different sources of infection
183	in: 1) the same community, 2) different communities in the same trial arm, 3) different
184	communities in the opposite trial arm and 4) in communities outside the trial area.
40-	

# 186 **Results**

188	Of the 5,114 trial participants who consented to a blood draw for viral genotyping and whose
189	HIV viral whole genomes were successfully deep-sequenced [1, 10], 3,832 met inclusion criteria
190	for phylogenetic analysis, and from those, we identified 82 directed opposite-sex transmission
191	pairs between ordered pairs of the 30 communities in the BCPP trial (Supplementary Figure 1)
192	[10]. Of the 82 source-recipient pairs, 51 (21 female-to-male, 30 male-to-female) were
193	identified between HIV viral genomes sampled during the baseline period of the trial compared
194	to 31 (16 female-to-male, 15 male-to-female) where the recipient's genome was sampled post-
195	baseline. We defined the post-baseline period as at least one year after baseline household
196	survey activities had concluded in a community such that the intervention could have taken
197	effect.
198	
199	Relationship between the drive distance separating pairs of communities and the risk of
200	transmission between them
201	
202	We first demonstrate a relationship between the drive distance separating communities
203	in the BCPP trial and the risk of HIV-1 transmission between them (Table 1 and Figure 1). We
204	define the risk of transmission as the expected probability of viral-linkage between deep-
205	sequenced HIV viruses of individuals with HIV randomly sampled from their respective
206	communities. Figure 1 and Table 1 show that the risk of transmission decreases as the drive
207	distance separating community pairs increases, specifically by 27% [95% Confidence Interval

208	(CI): 3 - 45] per 100 kilometers. Note that the decrease in risk of transmission per 100
209	kilometers is computed from Table 1 as (27% = $100\% * [1 - exp(100 \text{ km} * -0.0031)]$ ). Beyond
210	the effect of distance, the risk of transmission between individuals who reside within the same
211	community was approximately 35-fold [13 - 98] higher at baseline and 8-fold [2 - 26] higher
212	post-baseline compared to that between individuals residing in different communities. Note
213	that the fold-change in the risk of transmission is computed from Table 1 as 35 = exp (3.56) at
214	baseline and 8 = exp (2.05) post-baseline.
215	
216	Estimating the relative contribution of different sources of infection residing inside versus
217	outside the trial area
218	
219	Next, using this model to estimate transmissions from communities that were not in the
219 220	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control
219 220 221	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different
219 220 221 222	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non-
219 220 221 222 222 223	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial
<ul> <li>219</li> <li>220</li> <li>221</li> <li>222</li> <li>223</li> <li>224</li> </ul>	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial communities as communities outside of the 30 communities that participated in the BCPP trial.
219 220 221 222 223 223 224 225	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial communities as communities outside of the 30 communities that participated in the BCPP trial. We estimated that individuals in non-trial communities accounted for most of the transmissions
219 220 221 222 223 224 225 226	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial communities as communities outside of the 30 communities that participated in the BCPP trial. We estimated that individuals in non-trial communities accounted for most of the transmissions that occurred to recipients in trial communities, with point estimates ranging from 84% to 92%
219 220 221 222 223 224 225 226 227	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial communities as communities outside of the 30 communities that participated in the BCPP trial. We estimated that individuals in non-trial communities accounted for most of the transmissions that occurred to recipients in trial communities, with point estimates ranging from 84% to 92% in intervention communities and 73% to 92% in control communities (Figure 2). On average,
219 220 221 222 223 224 225 226 227 228	Next, using this model to estimate transmissions from communities that were not in the trial, we estimate proportions of transmissions into intervention communities and control communities of the BCPP trial that occurred from individuals in the same community; different communities in the same trial arm; different communities in the opposite trial arm; and non- trial communities (see "Supplementary Appendix sections S1.1 and S1.2"). We define non-trial communities as communities outside of the 30 communities that participated in the BCPP trial. We estimated that individuals in non-trial communities accounted for most of the transmissions that occurred to recipients in trial communities, with point estimates ranging from 84% to 92% in intervention communities and 73% to 92% in control communities (Figure 2). On average, 90% [95% Confidence Interval (CI): 81 – 93] of transmissions to recipients in intervention

- 12 -

estimated to have sources who lived in non-trial communities (Figure 3). This finding is
consistent with communities in the BCPP trial being densely surrounded by communities
outside the trial area and aligns with the fact that the BCPP trial participants represented a
relatively small (7.6%) proportion of the national population.

235 Proximity to urban centers

236

237 Communities in the BCPP trial are distributed around three major urban areas that each have 238 relatively high numbers of people with HIV; these are Gaborone city in the South-East, Palapye 239 in the Central-East and Francistown city in the North/North-East (Figure 2 and Supplementary 240 Figure 2). Figure 2 shows that sexual partners in the same community had a greater impact on 241 transmission in rural communities that are geographically isolated compared to in communities 242 that closely neighbor major urban centers. For example, Gumare intervention community and 243 Shakawe control community in the Northern region of Botswana received an estimated 9% [2 – 244 30] and 22% [8 - 55] of transmissions respectively from individuals in the same community; this 245 estimated percentage was lower for communities on the periphery of densely populated urban 246 areas such as Oodi intervention community 2% [0.4 – 7] and Bokaa control community 5% [2 – 247 15] in the South-East region. Furthermore, we found that the proportions of transmissions to 248 recipients in intervention communities from individuals in the same trial arm were similar 249 across the three major urban areas (Central-East: 5% [2 – 14], North/North-East: 6% [2 – 16], South-East: 4% [1 - 14] ( $\chi^2 = 0.8, df = 2, P = 0.7$ ). 250

## 252 Impact of communities in the opposite trial arm

253

254	Individuals in control communities contributed a higher proportion of transmissions to
255	intervention communities than the reverse. For example, the proportions of transmissions to
256	recipients in intervention communities from individuals in control communities ranged with
257	point estimates from 4.2% to 5.6%, compared to those to recipients in control communities
258	from individuals in intervention communities that ranged from 1.9% to 2.4% (Figure 2). On
259	average, 5.0% [4.5 – 5.2] of transmissions to recipients in intervention communities occurred
260	from individuals in control communities compared to 2.2% [0.7 – 5.2] of transmissions to
261	recipients in control communities that occurred from individuals in intervention communities,
262	consistent with a benefit of treatment-as-prevention (Figure 3). Furthermore, Figure 3 shows
263	that on average 2.9% [0.8 – 10.4] of transmissions to recipients in intervention communities
264	occurred from individuals in the same community and 1.9% [0.6 – 4.4] of transmissions
265	occurred from individuals in other intervention communities. In comparison, 8.2% [7.6 – 24.9]
266	of transmissions to recipients in control communities occurred from individuals in the same
267	community and 4.0% [3.1 – 4.3] of transmissions occurred from individuals in other control
268	communities.

270

# 271 Impact of a nationwide intervention

273	To evaluate what the impact of a national rollout of our HIV combination prevention
274	intervention would have been on recipients in trial communities, we estimated what the
275	number of transmissions would have been to recipients in trial communities if all (compared to
276	none) of the non-trial communities nationwide had also received the intervention (see
277	Supplementary Appendix section S1.2 "Counterfactual estimates"). We found that
278	transmissions to recipients in trial communities could have been reduced by 59% $[3 - 87]$ if the
279	intervention had been applied nationally (Figure 4). Note that the proportion of transmissions
280	in trial communities that could have been averted with a national rollout is computed from
281	modeled estimates of the total number of transmissions to recipients in trial communities from
282	sources inside trial communities as well as from sources in communities outside the trial area
283	(averted transmissions = 100% $*$ [ (# transmissions into trial communities from all sources
284	without intervention - # transmissions into trial communities from all sources with intervention)
285	/ # transmissions into trial communities from all sources without intervention] ). Furthermore,
286	this finding adds evidence that the impact of the BCPP trial intervention could be substantially
287	larger than that observed in the trial if applied nationally.

# 288 Discussion

289

290	Global targets set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) to have fewer
291	than 500,000 new infections by the year 2020 on a path to reach epidemic control by the year
292	2030 were missed. Relevant to this, several large community-randomized universal HIV test-
293	and-treat trials that were at the center of HIV prevention efforts in East and Southern Africa
294	showed mixed results [1-5]. To aid interpretation of the complex trial results and inform public
295	health policy decisions about effective HIV prevention strategies, we developed a statistical
296	modeling approach that uses directed sexual contacts inferred from deep-sequenced HIV virus
297	to quantify the relative contribution of different sources of infection, that might be inside trial
298	communities or outside the trial area. Briefly, to demonstrate the relative extent to which
299	transmissions in intervention communities and control communities of the BCPP trial in
300	Botswana occurred from individuals in the same community; different communities in the same
301	trial arm; different communities in the opposite trial arm; and communities outside the trial
302	area we first inferred directed opposite-sex transmission events between trial communities
303	using deep-sequence phylogenetics. Then we used the directed opposite-sex transmission
304	events that were inferred from deep-sequence phylogenetics together with the pairwise drive
305	distances between trial communities and the intervention status of source communities to
306	statistically model the risk of transmission between trial communities. After that we provided
307	pairwise drive distances between communities that participated in the 2011 Botswana
308	population and housing census to the model as input to estimate the risk of transmission
309	(expected probability of viral genetic-linkage had the cases been sequenced) between

- 16 -

communities nationally. Then, to estimate the number of transmissions into trial communities
from all communities nationally we combined estimates of the risk of transmission to recipients
in trial communities from communities nationally with population-size estimates from the 2011
Botswana population and housing census [14] and district-level HIV prevalence estimates from
the 2013 Botswana AIDS Impact Survey (BAIS 2013) [15].

315

Power analyses and model predictions for the primary endpoints of the BCPP trial in Botswana 316 317 and the PopART trial in South Africa and Zambia assumed that 20% [95% CI: 15 - 25] and 5% of 318 sexual partnerships would involve a partner outside one's own community, respectively [2, 8, 319 16]. Strikingly, we found that individuals in non-intervention communities accounted for most 320 of the transmissions that occurred to recipients in intervention communities; with an estimated 321 90% [81 – 93] of transmissions attributable to individuals from non-trial communities and 5.0% 322 [4.5 – 5.2] of transmissions attributable to individuals from control communities. For context, a 323 phylogenetic study that used consensus sequences of the HIV-1 POL (polymerase) gene to 324 estimate the relative contribution of local transmission versus external introductions to HIV-1 325 incidence in the Africa Health Research Institute (AHRI) study population, a rural and peri-urban 326 population located immediately adjacent to the TasP trial study area in KwaZulu-Natal, South 327 Africa, estimated that 35% [20 – 60] of new infections in the study population were external 328 introductions that occurred from sexual partners outside the study area [5, 17]. Most of the 329 external introductions in the AHRI phylogenetics study were estimated to be from sources 330 within the national borders of South Africa with few cross-border external introductions from Botswana, Malawi, Mozambique, Zambia and Zimbabwe (see Figure 2B in [17]). BCPP trial 331

332 communities closely neighbor three major urban areas in Botswana (Gaborone city in the 333 South-East, Palapye in the Central-East and Francistown city in the North/North-East), and 334 people tend to be fairly mobile in Botswana. By comparison, the AHRI study area is relatively 335 distantly located from the major urban area in the KwaZulu-Natal province of South Africa (200 336 kilometers north of Durban city), therefore, it is unsurprising that there would be more external 337 introductions to BCPP trial communities compared to the AHRI study population. In line with 338 the finding from the AHRI phylogenetics study, a clustering analysis conducted by the PANGEA-339 HIV consortium on HIV-1 viral consensus sequences from the AHRI study population in South 340 Africa, BCPP trial in Botswana, MRC study population in Uganda, PopART study population in 341 Zambia and Rakai study population in Uganda found few clusters including cohorts from 342 different countries. The limited cross-border external introductions into Botswana suggest that 343 extending the BCPP trial intervention to all communities nationally to target more sources 344 could effectively reduce the occurrence of new infections. 345 346 Accordingly, we estimated in a counterfactual modeling scenario to demonstrate the impact of 347 a national application of the intervention that applying the BCPP trial intervention in all 348 communities nationwide (versus none) could have reduced transmissions to recipients in trial 349 communities by 59% [3 – 87]) at the time (compared with the 30% reduction that was observed 350 in the BCPP HIV incidence cohort). This was done under an assumption that the intervention 351 effect that was observed in intervention communities would be similar when extended to a larger geographical area and would reduce the risk of transmission between any two individuals 352 residing in Botswana, rather than (as in the trial) any two individuals residing in intervention 353

- 18 -

354	communities. In practice, the intervention effect could vary owing to differences in
355	transmission patterns of different population sub-groups and geographical locations. These
356	findings suggest that substantial reductions in transmission could be achieved if the
357	intervention is applied nationwide and that estimating the relative contribution of various
358	sources of transmission (attributable fraction of cases) could help to guide targeted applications
359	of the intervention where resources are limited. The timing of the implementation of a
360	universal test-and-treat intervention could be crucial. Fast roll-out could limit the spread of
361	infection and shorten the time to reach epidemic control. Furthermore, the estimated
362	reductions in transmissions with a nationwide intervention suggest that the universal HIV test-
363	and-treat intervention could be used as a foundation for incidence reduction upon which other
364	interventions could be layered to close the gap to reach epidemic control.
365	

366 A key strength of our statistical approach is that we demonstrate how deep-sequence pathogen 367 genomics can be used at scale to assess interventions in cluster-randomized trials of infectious 368 disease prevention. Our analysis is based on the central assumptions that transmission patterns 369 in communities randomized to the control arm of the trial are representative of those found in 370 non-trial communities, and that, the population-size and HIV prevalence of communities are 371 known; and that the HIV prevalence in administrative districts is representative of that in 372 communities (see Supplementary Appendix section S1.1 "Population-based molecular source 373 attribution model"). There are some limitations to our analysis: First, our statistical approach is 374 informed by pairwise drive distances separating pairs of communities and could be improved 375 with mobile phone data to gain insight on daily commutes and seasonal migration for work (for

376 example: farming and mining) and holidays. Second, HIV viral sequences of cases were 377 collected only in trial communities. However, Figure 1 and Table 1 show a relationship between 378 the drive distance separating pairs of communities in the BCPP trial and the estimated risk of 379 transmission between them. This relationship allows us to use the drive distances separating 380 trial communities and non-trial communities to estimate the expected probability of viral 381 linkage to source cases in non-trial communities had cases in non-trial communities also been 382 sequenced. Third, even though we did not explicitly model the impact of community size on 383 risk of HIV-1 transmission to- and from- communities we found that there was generally a 384 positive correlation between the number of transmissions to recipients in trial communities 385 predicted by the post-baseline model in Table 1 and the opportunity for transmission to 386 recipients in trial communities. The opportunity for transmission to recipients in a community is 387 defined as the maximum distinct possible opposite-sex transmission pairs that could involve 388 recipients in that community and is based on the number of people with HIV in the source and 389 recipient communities (Supplementary Figure 4). To broaden insights, our statistical modeling 390 approach could be applied to estimate the relative contribution of various sources of infection 391 by age and sex in the other community-randomized universal HIV test-and-treat trials that have 392 assembled deep-sequence genomic data, for example the PopART trial in South Africa and Zambia. 393

394

Our findings have implications for public health policy and for the design of effective HIV
 prevention strategies. By deconstructing the relative contribution of different sources of
 infection in intervention communities versus control communities this work aids interpretation

- 20 -

398 of the complex universal HIV test-and-treat trials in which the intervention is administered on 399 one group (people with HIV) and the outcome (reduction in number of new cases) is measured 400 on another group (people in the same community without HIV). For example, our findings 401 elucidate the potential impact of a nationwide intervention and provide insight on the extent to 402 which the BCPP intervention was diluted by spillover infections from control communities and 403 from communities outside the trial area. Furthermore, our findings inform on-going public 404 health policy discussions on whether the HIV testing component in national HIV prevention 405 programs should be centered on facility-based testing at clinics and index-based testing of 406 family and sexual contacts of people with HIV or anchored on intensive universal household-407 based HIV testing as was done in the trials. For example, this study shows how the combination 408 of universal household-based HIV testing and routine HIV testing in health facilities - as was 409 done in the combination prevention intervention in the BCPP trial - allows us to infer 410 transmission patterns within and between communities to guide HIV prevention strategies. 411 412 In sum, this work shows that individuals residing in communities outside the BCPP trial area 413 accounted for most of the transmissions to recipients in intervention communities, limiting the 414 impact of the BCPP trial intervention. Furthermore, substantial gains in reducing transmission 415 could be made with a nationwide application of the intervention. With the introduction of 416 interventions at the community-level (universal test-and-treat) and individual-level (pre-417 exposure prophylaxis and self-testing) our analysis suggests that genomic surveillance could 418 provide a crucial platform to assess interventions allowing us to track how pathogens spread and evolve overtime in response to different interventions. For example, samples collected for 419

- 21 -

420	routine viral load testing could also be sequenced to track the directional spread of infection
421	within and between communities and between age-sex population sub-groups. This could help
422	to identify population sub-groups and communities in which HIV prevention interventions need
423	to be further strengthened to reduce transmission. Pairing genomic information with
424	information from studies that explicitly quantify the impact of social behavioral change on
425	interventions could aid the interpretation of HIV prevention studies and evidence-based policy
426	design. Based on our findings, we recommend that studies of infectious disease prevention
427	consider the impact of sources of transmission beyond the reach of the intervention when
428	evaluating interventions to inform public health programs.

429

431	Supplementary Appendix S1 Statistical approach to estimate the relative contribution of
432	various sources of infection in cluster-randomized trials of infectious disease prevention
433	
434	
435	S1.1 Population-based molecular source attribution model
436	
437	In cluster-randomized trials of HIV prevention, where the randomization unit is communities,
438	new infections can arise from individuals: in the same community, in different communities in
439	the same trial arm, in different communities in the opposite trial arm and in non-trial
440	communities. The aim of this analysis is to estimate the proportions of transmissions in trial
441	communities that are attributable to the above-mentioned sources of infection. Suppose we
442	would like to estimate the number of transmissions in the population, $z_{ij}$ that occurred to
443	individuals in community <i>i</i> from individuals of the opposite-sex in community <i>j</i> . We refer to
444	community <i>i</i> as a recipient community and community <i>j</i> as a source community. Notice that, <i>i</i> =
445	<i>j</i> when estimating the number of transmissions that occurred from individuals in the same
446	community. We estimate the number of transmissions into a recipient community <i>i</i> from a
447	source community j at period t using two quantities, $NH_{ij}(t)$ which is treated as known and
448	represents the maximum number of distinct possible (opposite-sex) transmission pairs in the
449	population between the two communities at period $t$ and, $\pi_{ij}(t)$ the risk of transmission
450	between the two communities at period t, that is, the expected probability of viral-linkage
451	between deep-sequenced HIV viruses of individuals randomly sampled from the respective
452	communities. More precisely, we consider the model

- 23 -

453

454

$$z_{ij}(t) = NH_{ij}\pi_{ij}(t), \tag{1a}$$

455 where 
$$\pi_{ij}(t) = \frac{E(x_{ij}^{pairs}(t))}{n_{ij}^{seq}(t)}$$
 and  $x_{ij}^{pairs}(t) \sim Negbin(E(x_{ij}^{pairs}(t)), \theta)$ , (1b)

456 and where 
$$\ln(\frac{E(x_{ij}^{pairs}(t))}{n_{ij}^{seq}(t)}) = \beta_0 + \beta_1 c_{ij} + \beta_2 s_{ij} + \beta_3 d_{ij},$$
 (1c)

457 or equivalently 
$$\ln(E(x_{ij}^{pairs}(t))) = \ln(n_{ij}^{seq}(t)) + \beta_0 + \beta_1 c_{ij} + \beta_2 s_{ij} + \beta_3 d_{ij}$$
 (1d)

458

459 with data and quantities

460	N <sub>i</sub>	population-size of community <i>i</i>
461	N <sub>fi</sub>	female population-size of community <i>i</i>
462	$N_{m_i}$	male population-size of community <i>i</i>
463	$N_j$	population-size of community <i>j</i>
464	$N_{f_j}$	female population-size of community <i>j</i>
465	$N_{m_j}$	male population-size of community <i>j</i>
466	$H_i$	HIV prevalence of community <i>i</i>
467	$H_{f_i}$	female HIV prevalence of community <i>i</i>
468	$H_{m_i}$	male HIV prevalence of community <i>i</i>
469	$H_j$	HIV prevalence of community <i>j</i>
470	$H_{f_j}$	female HIV prevalence of community <i>j</i>
471	$H_{m_j}$	male HIV prevalence of community <i>j</i>
472	$NH_i = N_i * H_i$	number of people with HIV in community <i>i</i>

473	$NH_{f_i} = N_{f_i} * H_{f_i}$	number of females with HIV in community <i>i</i>
474	$NH_{m_i} = N_{m_i} * H_{m_i}$	number of males with HIV in community <i>i</i>
475	$NH_j = N_j * H_j$	number of people with HIV in community <i>j</i>
476	$NH_{f_j} = N_{f_j} * H_{f_j}$	number of females with HIV in community <i>j</i>
477	$NH_{m_j} = N_{m_j} * H_{m_j}$	number of males with HIV in community <i>j</i>
478	$n_i^{seq}(t)$	number of individuals randomly sampled from community <i>i</i> at
479		period t whose viral whole genomes were successfully deep-
480		sequenced
481	$n_{f_i}^{seq}(t)$	number of females randomly sampled from community <i>i</i> at
482		period t whose viral whole genomes were successfully deep-
483		sequenced
484	$n_{m_i}^{seq}(t)$	number of males randomly sampled from community <i>i</i> at
485		period <i>t</i> whose viral whole genomes were successfully deep-
486		sequenced
487	$n_j^{seq}(t)$	number of individuals randomly sampled from community <i>j</i> at
488		period t whose viral whole genomes were successfully deep-
489		sequenced
490	$n_{f_j}^{seq}(t)$	number of females randomly sampled from community <i>j</i> at
491		period t whose viral whole genomes were successfully deep-
492		sequenced
493	$n_{m_j}^{seq}(t)$	number of males randomly sampled from community <i>j</i> at

494	period t whose viral whole genomes were successfully deep-
495	sequenced
496	$n_{ij}^{seq}(t) = n_{m_i}^{seq}(t) * n_{f_j}^{seq}(t) + n_{f_i}^{seq}(t) * n_{m_j}^{seq}(t)$ maximum number of distinct possible
497	(opposite-sex) transmission pairs at period t between
498	individuals randomly sampled from communities <i>i</i> and <i>j</i> and
499	whose viral whole genomes were successfully deep-
500	sequenced
501	$NH_{ij}(t) = NH_{m_i} * n_{f_j}^{seq}(t) + NH_{f_i} * n_{m_j}^{seq}(t)$ maximum number of distinct possible
502	(opposite-sex) transmission pairs in the population at period t
503	between communities <i>i</i> and <i>j</i>
504	$x_{ij}^{pairs}(t)$ number of transmission pairs identified from the deep-
505	sequenced HIV virus of individuals randomly sampled from
506	communities <i>i</i> and <i>j</i> at period <i>t</i>
507	c <sub>ij</sub> source community is a nonintervention community, that is, a
508	control community or non-trial community (yes = 1, no = 0)
509	$s_{ij}$ source community and recipient community are the same, that
510	is, same community transmission (yes = 1, no = 0)
511	$d_{ij}$ distance in kilometers separating the source community and
512	recipient community
513	

514 and estimated parameters

515 
$$\pi_{ij}(t) = \frac{E(x_{ij}^{pairs}(t))}{n_{ij}^{seq}(t)}$$
 risk of HIV transmission between communities *i* and *j* at period *t*  
516  $\theta$  overdispersion parameter  
517  $\beta_0, \beta_1, \beta_2, \beta_3$  fixed effects regression parameters

518

519 For clarity, the maximum number of distinct possible (opposite-sex) transmission pairs between 520 individuals randomly sampled from communities *i* and *j* during the baseline period of the trial is,  $n_{ij}^{seq}(t_{baseline}) = n_{m_i}^{seq}(t_{baseline}) * n_{f_i}^{seq}(t_{baseline}) + n_{f_i}^{seq}(t_{baseline}) * n_{m_i}^{seq}(t_{baseline})$ . By 521 comparison, the maximum number of distinct possible (opposite-sex) transmission pairs 522 523 between individuals randomly sampled from communities *i* and *j* during the post-baseline period of the trial is,  $n_{ij}^{seq}(t_{post-baseline}) = n_{m_i}^{seq}(t_{baseline} + t_{post-baseline}) *$ 524  $n_{f_i}^{seq}(t_{post-baseline}) + n_{f_i}^{seq}(t_{baseline} + t_{post-baseline}) * n_{m_i}^{seq}(t_{post-baseline})$ . The central 525 526 assumptions of this model are that the transmission pairs identified between samples from 527 communities *i* and *j* are independent, and that transmission patterns in communities 528 randomized to the control arm of the trial are representative of those found in non-trial 529 communities. The simplifying assumption of independence is appropriate when identified 530 transmission events mostly comprise small two-person clusters as found in the BCPP data and 531 could be less-suited for large clusters typical of super spreader events. Furthermore, we assume 532 that population-size and HIV prevalence of communities *i* and *j* are known, and that the HIV 533 prevalence in administrative districts is representative of that in communities. We acknowledge 534 that community-level HIV prevalence estimates can be obtained directly with the methods of [19] and reserve such computation for future study. 535

536

# 537 S1.2 Application to BCPP study data

538

539	We applied the population-based molecular source attribution model in section S1.1 to
540	estimate the relative contribution of sources of infection (inside versus outside the trial area) to
541	transmissions that occurred to recipients in BCPP trial communities. Because viral genotyping
542	was only done in trial communities, we used census data to combine information from trial
543	communities with that from communities outside the trial area. First, we estimated the
544	maximum number of distinct possible (opposite-sex) transmission pairs in the population
545	between ordered pairs (488 x 29) of the 488 communities that participated in the 2011
546	Botswana population and housing census (see methods "Pairwise drive distance data" and
547	"Population-size and HIV prevalence estimates"). Because there were no individuals sampled
548	from "Digawana" intervention community during the post-baseline period whose HIV-1 virus
549	was successfully deep-sequenced and met inclusion criteria for phylogenetic analysis, we
550	excluded ordered community pairs that had "Digawana" as a recipient (destination)
551	community. Afterwards, as described in equations 1b to 1d, we used directed opposite-sex
552	transmission pairs identified between ordered pairs of the 30 communities in the BCPP trial
553	(Supplementary Figure 1) to estimate the risk of transmission, that is, expected probability of
554	viral linkage between those ordered community pairs during the baseline and post-baseline
555	periods of the trial (see Table 1, Figure 1 and methods "Deep-sequence phylogenetics data" and
556	"Pairwise drive distance data"). Estimates were obtained using parametric maximum likelihood
557	estimation with the nbreg module in Stata 13.1 and the glm.nb function in the MASS package

- 28 -

v7.3-54 in R v4.1.2 [13]. We excluded ordered community pairs that had "Digawana" as a 558 559 recipient (destination) community from the input datasets used to model the risk of 560 transmission for the same reasons as described above, in particular, there were no individuals 561 sampled from "Digawana" intervention community during the post-baseline period whose HIV-562 1 virus was successfully deep-sequenced and met inclusion criteria for phylogenetic analysis. 563 Consequently, the input datasets used to fit the baseline and post-baseline models to estimate 564 the risk of transmission between communities in the BCPP trial comprised 870 distinct 565 observations ( $870 = 30 \times 30 - 30$ ) that each contained six pieces of information: 1) ordered 566 community pair, that is, source community and recipient community, 2) non-intervention 567 community status, 3) same community transmission status, 4) drive distance in kilometers 568 separating the source community and recipient community, 5) number of transmission pairs 569 identified (observed) between individuals randomly sampled from the source community and 570 recipient community during the relevant time period, and 6) the maximum number of distinct 571 possible (opposite-sex) transmission pairs between individuals randomly sampled from the 572 source community and recipient community during the relevant time period. Next, we used the 573 post-baseline model of the risk of transmission between ordered pairs of communities in the 574 BCPP trial to predict the risk of transmission to recipients in intervention communities and 575 control communities from the 488 census communities. The risk prediction dataset comprised 576 (14,152 = 488 x 29) distinct observations that each contained five pieces of information. These 577 were: the same first four pieces of information as those in the input dataset for the post-578 baseline model of the risk of transmission, and for the fifth piece of information, we set the 579 natural-log of the maximum number of distinct possible (opposite-sex) transmission pairs

- 29 -

580 between individuals randomly sampled from the source community and recipient community during the relevant time period to zero, that is,  $\ln (n_{ii}^{seq}(t)) = 0$ . We set  $\ln (n_{ii}^{seq}(t)) = 0$  to 581 582 predict the risk of transmission (expected probability of viral linkage) instead of the expected 583 transmission counts. In each ordered community pair, we used the origin community in an 584 origin-destination pairing as a surrogate for the source community and the destination 585 community as a surrogate the recipient community. Predictions were made with the predict 586 function in the stats package in R v4.1.2. Then, as described in equation 1a, we estimated the 587 number of transmissions between each ordered pair of communities as the product of the 588 maximum number of distinct possible (opposite-sex) transmission pairs in the population 589 between the ordered community pairs and the estimated risk of transmission between them. 590 591 After estimating the number of transmissions that occurred at period t between all ordered 592 community pairs in the population that have community *i* as a recipient community, we denote

the total estimated number of transmissions to recipients in community *i* at period *t* as the
vector

$$\hat{z}_{i}(t) = (\hat{z}_{ia}(t), \ \hat{z}_{ib}(t), \ \hat{z}_{ic}(t), \ \hat{z}_{id}(t)),$$
(2)

596

where  $\hat{z}_{ia}(t)$  is the estimated number of transmissions from individuals within the same community, that is, community *i*,  $\hat{z}_{ib}(t)$  is the estimated number of transmissions from individuals in other communities that are in the same trial arm as community *i*,  $\hat{z}_{ic}(t)$  is the estimated number of transmissions from individuals in communities that are in the opposite trial arm to community *i* and  $\hat{z}_{id}(t)$  is the estimated number of transmissions from individuals

602 in non-trial communities. Then we estimate the proportions of transmissions to recipients in 603 community *i* from individuals (sources of infection) in different types of communities as 604  $\hat{\zeta}_{i}^{same \ community}(t) = \frac{\hat{z}_{ia}(t)}{(\hat{z}_{ia}(t) + \hat{z}_{ib}(t) + \hat{z}_{ic}(t) + \hat{z}_{id}(t))}$ 605 (3a) 606  $\hat{\zeta}_{i}^{same trial arm}(t) = \frac{\hat{z}_{ib}(t)}{(\hat{z}_{ia}(t) + \hat{z}_{ib}(t) + \hat{z}_{ic}(t) + \hat{z}_{id}(t))}$ 607 (3b) 608  $\hat{\zeta}_{i}^{opposite\ trial\ arm}(t) = \frac{\hat{z}_{ic}(t)}{(\hat{z}_{ia}(t) + \hat{z}_{ib}(t) + \hat{z}_{ic}(t) + \hat{z}_{id}(t))}$ 609 (3c) 610  $\hat{\zeta}_{i}^{non-trial\,community}\left(t\right) = \frac{\hat{z}_{id}(t)}{(\hat{z}_{ia}(t) + \hat{z}_{ib}(t) + \hat{z}_{ic}(t) + \hat{z}_{id}(t))} \ .$ 611 (3d) 612 613 614 Suppose community *i* was randomized to receive the intervention then the mean estimate of 615 the proportion of transmissions to recipients in intervention communities from individuals in 616 the same community is 617  $\widehat{\overline{\zeta}}_{i}^{same\ community}(t) = \frac{\sum \widehat{z}_{ia}(t)}{\sum \widehat{z}_{i}(t)}.$ 618 (4) 619 620 The same principle follows for the three other sources of infection: same trial arm, opposite 621 trial arm and non-trial community; wherein the numerator for the mean estimate is the sum of 622 the numerators of the individual community estimates and similarly, the denominator for the

623 mean estimate is the sum of the denominators of the individual community estimates (Figures624 2 and 3).

625

626 Counterfactual estimates

627	To model the impact of a nationwide intervention (Figure 4) we estimated what the number of
628	transmissions to recipients in trial communities would have been if all 488 census communities
629	had received the intervention ( $c_{ij} = 0$ ) compared to if none of the communities had received
630	the intervention ( $c_{ij}=1$ ). This was done under an assumption that the observed effect of the
631	BCPP trial intervention in intervention communities would be similar when extended to a larger
632	geographical area. However, there could be variation in the effect of the intervention that is
633	observed due to heterogeneous transmission patterns across different population sub-groups
634	and geographical locations. Because there were no individuals sampled from "Digawana"
635	intervention community during the post-baseline period whose HIV-1 virus was successfully
636	deep-sequenced and met inclusion criteria for phylogenetic analysis we excluded ordered
637	community pairs that had "Digawana" as a recipient (destination) community. We estimate that
638	a nationwide application of the intervention could have reduced transmissions to recipients in
639	trial community <i>i</i> by,

640

641 
$$\hat{\zeta}_{i}^{averted \ transmissions}(t) = \frac{\hat{z}^{None}_{i}(t) - \hat{z}^{All}_{i}(t)}{\hat{z}^{None}_{i}(t)}$$

- 642
- 643

and that on average transmissions across all trial communities could have been reduced by,

(5)

645

646 
$$\hat{\zeta}_{i}^{averted \ transmissions}(t) = \frac{\sum (\hat{z}^{None}_{i}(t) - \hat{z}^{All}_{i}(t))}{\sum \hat{z}^{None}_{i}(t)}.$$
 (6)

647

### 648 Alternative models

We considered alternative versions of the post-baseline model for the risk of transmission 649 650 between ordered pairs of communities in the BCPP trial that used transforms of the pairwise 651 drive distance separating communities (Supplementary Table 1). The linear model shown in 652 supplementary Table 1 and described in equations 1b through 1d was selected as the best 653 model based on Aikaike information criterion (AIC) and parsimony. We noted that sampling of 654 trial participants through clinics in the BCPP trial was only done in intervention communities but not in control communities resulting in an asymmetry between the intervention and control 655 656 arms of the trial. Therefore, we modeled the risk of transmission between ordered pairs of 657 communities in the BCPP trial excluding transmission pairs where both individuals were sampled at a clinic in an intervention community during the same trial period, that is, both 658 659 individuals sampled at baseline or post-baseline (Supplementary Table 2). We found similar 660 patterns to those observed in the baseline and post-baseline models in Table 1. The negative-661 binomial regression models used to estimate the risk of transmission between ordered pairs of 662 communities in the BCPP trial were fit with parametric maximum likelihood estimation with the 663 nbreg module in Stata 13.1 and the glm.nb function in the MASS package v7.3-54 in R v4.1.2 664 [13]. 665

## 667 Model diagnostics

668	We performed several diagnostics to assess the fit of the post-baseline model in Table 1 to the
669	directed transmission pairs identified between ordered pairs of communities in the BCPP trial.
670	First, we assessed if the model converged to the maximum likelihood of the data using a
671	likelihood grid search wherein the mean number of transmission pair counts predicted by the
672	post-baseline model in Table 1 was adjusted upwards and downwards by 10% and 20%. We
673	found that adjusting the predicted number of counts upwards or downwards did not improve
674	the log-likelihood suggesting that the model had converged on the maximum likelihood of the
675	data. Second, we compared the number of transmission pairs identified between ordered pairs
676	of communities in the BCPP trial with those that would be expected under the post-baseline
677	model in Table 1. There was little evidence to suggest that the observed counts differed
678	substantially from those expected under the model (Fisher exact $P = 0.792$ ) (Supplementary
679	Table 3). Third, we also used a simulation-based approach to compare the distribution of
680	observed quantile residuals with that expected under the post-baseline model in Table 1 and
681	found little appreciable difference between the observed and expected distributions
682	(Supplementary Figure 3). The simulation-based approach was performed using the DHARMa
683	package v0.4.6 in R v4.1.2.
684	
685	

686 Confidence intervals

687 We used an empirical bootstrap approach to compute 95% confidence intervals for the

688 estimated proportions of transmissions attributable to different sources of infection wherein

- each bootstrap procedure was performed with 1,000 replicates. The lower and upper bounds of
- the confidence intervals represent the 2.5% and 97.5% quantiles, respectively.
- 691
- 692
- 693 **Data and Code availability:** All relevant data are within the paper, figures and tables. A code
- 694 repository has been made available at the following URL:
- 695 https://github.com/magosil86/spillover-infections
- 696
- 697
- 698
- 699
- 700

701		References
702 703	1.	Makhema, J., et al., Universal Testing, Expanded Treatment, and Incidence of HIV
704		Infection in Botswana. New England Journal of Medicine, 2019. <b>381</b> (3): p. 230-242.
705	2.	Hayes, R.J., et al., Effect of Universal Testing and Treatment on HIV Incidence — HPTN
706		071 (PopART). New England Journal of Medicine, 2019. <b>381</b> (3): p. 207-218.
707	3.	Havlir, D.V., et al., HIV Testing and Treatment with the Use of a Community Health
708		Approach in Rural Africa. New England Journal of Medicine, 2019. <b>381</b> (3): p. 219-229.
709	4.	Iwuji, C.C., et al., Universal test and treat and the HIV epidemic in rural South Africa: a
710		phase 4, open-label, community cluster randomised trial. Lancet HIV, 2018. 5(3): p.
711		e116-e125.
712	5.	Abdool Karim, S.S., HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. New
713		England Journal of Medicine, 2019. <b>381</b> (3): p. 286-288.
714	6.	Carnegie, N.B., R. Wang, and V.D. Gruttola, Estimation of the Overall Treatment Effect in
715		the Presence of Interference in Cluster-Randomized Trials of Infectious Disease
716		Prevention. Epidemiologic Methods, 2016. 5(1): p. 57-68.
717	7.	Halloran, M.E., et al., Direct and indirect effects in vaccine efficacy and effectiveness.
718		American Journal of Epidemiology, 1991. <b>133</b> (4): p. 323-31.
719	8.	Wang, R., et al., Sample size considerations in the design of cluster randomized trials of
720		combination HIV prevention. Clinical Trials, 2014. 11(3): p. 309-318.

721	9.	Wirth, K.E., et al., Population uptake of HIV testing, treatment, viral suppression, and
722		male circumcision following a community-based intervention in Botswana (Ya
723		<i>Tsie/BCPP): a cluster-randomised trial.</i> Lancet HIV, 2020. <b>7</b> (6): p. e422-e433.
724	10.	Magosi, L.E., et al., Deep-sequence phylogenetics to quantify patterns of HIV
725		transmission in the context of a universal testing and treatment trial - BCPP/Ya Tsie trial.
726		eLife, 2022. <b>11</b> .
727	11.	Ratmann, O., et al., Inferring HIV-1 transmission networks and sources of epidemic
728		spread in Africa with deep-sequence phylogenetic analysis. Nature Communications,
729		2019. <b>10</b> (1): p. 1411.
730	12.	Wymant, C., et al., PHYLOSCANNER: Inferring Transmission from Within- and Between-
731		Host Pathogen Genetic Diversity. Molecular Biology and Evolution, 2017. 35(3): p. 719-
732		733.
733	13.	R Core Team, R: A language and environment for statistical computing. 2021, R
734		Foundation for Statistical Computing: Vienna, Austria.
735	14.	U.S. Census Bureau Population Division, I.D.B., September 2018 release, available at
736		https://www.census.gov/data-tools/demo/idb/informationGateway.php, accessed in
737		July 2019, Botswana Annual Five-Year Age Group Population Estimates by Sex for 2000
738		to 2025: National and First-, Second-, and Third-Order Administrative Divisions. 2018.
739	15.	Statistics Botswana, Table 6: HIV Prevalence Rate by District. BOTSWANA AIDS IMPACT
740		SURVEY IV 2013. Statistical report. 2013.

- 37 -

- 741 16. Novitsky, V., et al., Phylogenetic relatedness of circulating HIV-1C variants in Mochudi,
- 742 Botswana. PLoS One, 2013. **8**(12): p. e80589.
- 743 17. Rasmussen, D.A., et al., *Tracking external introductions of HIV using phylodynamics*
- 744 reveals a major source of infections in rural KwaZulu-Natal, South Africa. Virus Evolution,
- 745 2018. **4**(2).
- 74618.Havlir, D., et al., What do the Universal Test and Treat trials tell us about the path to HIV
- 747 *epidemic control?* Journal of the International AIDS Society, 2020. **23**(2): p. e25455.
- 748 19. Dwyer-Lindgren, L., et al., *Mapping HIV prevalence in sub-Saharan Africa between 2000* 749 and 2017. Nature, 2019. 570(7760): p. 189-193.
- 750
- /50

### 752 Acknowledgements and Funding

- 753 We are grateful to participants and collaborators from the Botswana Combination Prevention
- 754 Project for their support during this work. We also thank the following colleagues for their
- helpful suggestions: Stephanie Marie Davis, Carol A. Ciesielski, Anindya De and Stacie Greby.
- 756 This study was supported by the National Institute of General Medical Sciences
- 757 (U54GM088558); the Fogarty International Center (FIC) of the U.S. National Institutes of Health
- 758 (D43 TW009610); and the President's Emergency Plan for AIDS Relief through the Centers for
- 759 Disease Control and Prevention (CDC) (Cooperative agreements U01 GH000447 and U2G
- 760 GH001911), NIH K24 AI131928 as well as the Morris-Singer Fund, the VK Fund for the Harvard
- 761 Center for Communicable Disease Dynamics and the Bill and Melinda Gates Foundation.

762

### 763 Disclaimer

- The findings and conclusions in this report are those of the author(s) and do not necessarily
- 765 represent the official position of the funding agencies.

**Table 1:** Negative-binomial regression models describing the expected probability of viral linkage between a pair of individuals randomly sampled from their respective communities in the BCPP trial.

Variable	Coefficient	Standard Error	95% Conf. Interval	P value
Baseline model: Before the intervention had taken effect				
Intercept	-11.59	0.54	-12.65 to $-10.53$	< 0.001
Transmission source: control community	0.63	0.42	-0.20 to $1.45$	0.14
Transmission type: same community	3.56	0.52	2.54 to 4.59	< 0.001
Drive distance between communities in kilometers	-0.0025	0.0012	-0.0047 to $-0.0002$	0.03
	AIC	215.98		
	N	870		
Post baseline model: After the intervention had taken effect				
Intercept	-11.31	0.54	-12.37 to $-10.24$	< 0.001
Transmission source: control community	0.90	0.51	-0.11 to $1.90$	0.08
Transmission type: same community	2.05	0.61	0.86 to 3.25	0.001
Drive distance between communities in kilometers	-0.0031	0.0014	-0.0059 to $-0.0003$	0.03
	AIC	137.26		
	N	870		

### Notes:

- Negative binomial regression models were fit to directed opposite-sex HIV-1 transmission pairs identified between ordered pairs of communities in the BCPP trial during the baseline (n = 51) and post-baseline (n = 31) periods (see methods "Deep-sequence phylogenetics data" and supplementary appendix sections S1.1 and S1.2).
- 2. Post-baseline is described as at least one year after baseline household survey activities had concluded in a community (see methods "BCPP study description").
- 3. The reference category is directed opposite-sex HIV-1 transmission pairs where individuals were randomly sampled from different communities in the BCPP trial and the source of transmission resides in an intervention community.
- 4. The intercept denotes the risk of HIV-1 transmission (i.e. expected probability of viral linkage) in the reference category.
- 5. Coefficients, standard errors and confidence bound values are presented on the linear scale and *p*-values are 2-sided.
- 6. **Transmission source:** *control community* denotes the effect on the risk of HIV-1 transmission when the source of transmission resides in a control community.
- 7. **Transmission type:** *same community* denotes the effect on the risk of HIV-1 transmission when both the source and recipient reside within the same community.
- 8. Drive distance between communities in kilometers denotes the effect on the risk of HIV-1 transmission for a 1 kilometer increase in the drive distance separating a pair of communities.



Figure 1. The risk of HIV-1 transmission between communities in the BCPP trial decreases as the drive distance separating them increases. The plot shows the expected probability of viral linkage, that is, risk of transmission between a pair of individuals randomly sampled from their respective communities in the BCPP trial. The expected probability of viral linkage was predicted with the post-baseline model in Table 1. To improve visibility panel A is a zoomed-in plot of the plot in panel B. Estimates for intervention community sources are shown in purple and those for control community sources are depicted in green. The solid curves and ribbons show the risk of transmission predicted by the post-baseline model between different communities in the BCPP trial and the associated uncertainty in the estimates. By comparison, the solid crosses depict the risk of transmission predicted by the post-baseline model within the same community. The squares and filled circles show the raw data for the 870 ordered community pairs of the 30 BCPP trial communities that were used to predict the expected probability of viral linkage within the same community (squares) or between different communities (filled circles). There were 15 intervention communities and 15 control communities in the BCPP trial. Because the "Digawana" intervention community had no participants with successfully sequenced samples during the post baseline period, community pairs with "Digawana" as a destination (recipient) community were excluded from the model (870 = 30 x 30 - 30). Among the 870 ordered community pairs, 14 were same community pairs with an intervention community as the origin (source) of transmission; 15 were same community pairs with a control community as the source of transmission, 421 were different community pairs with an intervention community as the source of transmission and 420 were different community pairs with a control community as the source of transmission. For each of the 870 ordered community pairs, the probability of viral linkage was computed from the raw data as the proportion of directed opposite-sex transmission pairs identified out of the total possible distinct opposite-sex transmission pairs among sampled participants.



**Figure 2.** Estimated HIV-1 transmissions into communities in the BCPP trial from different sources of infection. Panel A. A voronoi tesselation map of communities (n = 488) in the 2011 Botswana population and housing census showing that communities in the BCPP trial are densely surrounded by communities outside the trial area i.e. non-trial communities. To complement Panel A, Panel B shows the names of the intervention communities and control communities in the BCPP trial within the context of administrative districts and census tracts. Panel C shows, in increasing shades of purple, the estimated proportions of HIV-1 transmissions to recipients in intervention communities. Note that "Digawana" intervention community is omitted from panel C because there were no successfully sequenced post-baseline samples in the community. Panel D shows, in increasing shades of green, the same for recipients in control communities. Most of the transmissions to recipients in BCPP trial communities originated from individuals in non-trial communities.



Figure 3. Mean estimates of HIV-1 transmissions that occurred to recipients in intervention communities and control communities in the BCPP trial from different sources of infection. The barplots show, in increasing shades of blue, the estimated proportions of HIV-1 transmissions to recipients in intervention communities and control communities from individuals in the same community (intervention: 2.9% [95% CI: 0.8-10.4], control: 8.2% [7.6-24.9]), communities in the same trial arm (intervention: 1.9% [0.6-4.4], control: 4.0% [3.1-4.3]), communities in the opposite trial arm (intervention: 5.0% [4.5-5.2], control: 2.2% [0.7-5.2]), and from non-trial communities (intervention: 90.1% [81.1-93.1], control: 85.6% [73.6-90.5]). The mean estimate of the proportion of HIV-1 transmissions to recipients in intervention sources, that is, from individuals in the same intervention community and from individuals in other intervention communities was 4.9% [95% CI: 1.7-14.4].



Figure 4. Counterfactual estimates of HIV-1 transmissions into BCPP trial communities showing the impact of a nationwide intervention. The grouped barplot shows the estimated number of transmissions to recipients in trial communities in the presence and absence of a nationwide intervention. Among the BCPP trial communities shown intervention communities are distinguished from control communities with an asterisk. The BCPP trial matched communities into 15 pairs based on geographical proximity to major urban areas, population-size and age structure, and access to health services. On average, a nationwide intervention could have reduced transmissions to recipients in trial communities by 59% [95% CI: 3-87]. "Digawana" intervention community was excluded because there were no successfully sequenced post-baseline samples in the community that met inclusion criteria for phylogenetic analysis.

**Supplementary Table 1:** A comparison of three negative-binomial regression models that describe the expected probability of viral linkage between a pair of individuals randomly sampled from their respective communities in the BCPP trial. The models are fit *(with and without) a transformation of the drive distance between communities*.

Variable	Coefficient	Standard Error	95% Conf. Interval	P value
Linear model				
Intercept	-11.31	0.54	-12.37 to -10.24	< 0.001
Transmission source: control community	0.90	0.51	-0.11 to $1.90$	0.08
Transmission type: same community	2.05	0.61	0.86 to 3.25	0.001
Drive distance between communities in kilometers	-0.0031	0.0014	-0.0059 to $-0.0003$	0.03
	AIC	137.26		
	N	870		
Model with log transformed drive distance				
Intercept	-8.23	1.36	-10.90 to $-5.57$	< 0.001
Transmission source: <i>control community</i>	0.96	0.53	-0.08 to 2.01	0.07
Transmission type: same community	-1.04	1.41	-3.80 to $1.73$	0.46
$Log_e$ (drive distance between communities in kilometers)	-0.77	0.26	-1.28 to $-0.25$	0.004
	AIC	137 98		
	N	870		
Model with squared drive distance				
Intercept	-11.11	0.63	-12.35 to $-9.88$	< 0.001
Transmission source: control community	0.89	0.51	-0.11 to $1.90$	0.08
Transmission type: same community	1.86	0.70	0.48 to 3.24	0.008
Drive distance between communities in kilometers	-0.0046	0.0033	-0.0110 to $0.0017$	0.15
Squared (drive distance between communities in kilometers)	1.70E - 06	2.75E - 06	-3.69E - 06 to $7.08E - 06$	0.54
	AIC	139.03		
	N	870		

### Notes:

- 1. All models were fit to directed opposite-sex HIV-1 transmission pairs (n = 31) identified between ordered pairs of communities in the BCPP trial during the post-baseline period (see methods "Deep-sequence phylogenetics data" and supplementary appendix sections S1.1 and S1.2).
- 2. The linear model is the same as the post-baseline model in Table 1.
- 3. The reference category is directed opposite-sex HIV-1 transmission pairs where individuals were randomly sampled from different communities in the BCPP trial and the source of transmission resides in an intervention community.
- 4. The intercept denotes the risk of HIV-1 transmission (i.e. expected probability of viral linkage) in the reference category.
- 5. Coefficients, standard errors and confidence bound values are presented on the linear scale and p-values are 2-sided.
- 6. **Transmission source:** *control community* denotes the effect on the risk of HIV-1 transmission when the source of transmission resides in a control community.
- 7. **Transmission type:** *same community* denotes the effect on the risk of HIV-1 transmission when both the source and recipient reside within the same community.
- 8. Drive distance in the linear model denotes the effect on the risk of HIV-1 transmission for a 1 kilometer increase in the drive distance separating a pair of communities.
- 9. Drive distance in the log transformed distance model denotes the effect on the risk of HIV-1 transmission with a unit increase in the Log<sub>e</sub>(drive distance) separating a pair of communities.
- 10. **Drive distance** in the **squared distance model** denotes the effect on the risk of HIV-1 transmission with a 1km increase and a  $1km^2$  increase in the drive distance separating a pair of communities.

**Supplementary Table 2:** Negative-binomial regression models describing the expected probability of viral linkage between a pair of individuals randomly sampled from their respective communities in the BCPP trial. Compared with Table 1, the models *exclude potential partner co-visit events to clinics in intervention communities during baseline or post-baseline*.

Variable Baseline model: Before the intervention had taken effect	Coefficient	Standard Error	95% Conf. Interval	P value
Intercept	-11.44	0.51	-12.44 to $-10.44$	< 0.001
Transmission source: control community	0.57	0.31	-0.05 to $1.18$	0.07
Transmission type: same community	3.46	0.50	2.48 to 4.43	< 0.001
Drive distance between communities in kilometers	-0.0026	0.0011	-0.0049 to $-0.0004$	0.02
	AIC	214.21		
	Ν	870		
Post baseline model: After the intervention had taken effect				
Intercept	-11.50	0.52	-12.51 to $-10.48$	< 0.001
Transmission source: control community	1.30	0.48	0.35 to 2.25	0.01
Transmission type: same community	2.09	0.63	0.86 to 3.32	0.001
Drive distance between communities in kilometers	-0.0038	0.0014	-0.0065  to  -0.0011	0.01
	AIC	151.65		
	Ν	870		

### Notes:

- Negative binomial regression models were fit to directed opposite-sex HIV-1 transmission pairs identified between ordered pairs of communities in the BCPP trial at baseline (n = 49 / 51) and post-baseline (n = 27 / 31), excluding transmission pairs where both individuals visited a clinic within the same intervention community during the same period of the trial i.e. baseline or post-baseline (see supplementary appendix sections S1.1 and S1.2).
- 2. Post-baseline is described as at least one year after baseline household survey activities had concluded in a community.
- 3. The reference category is directed opposite-sex HIV-1 transmission pairs where individuals were randomly sampled from different communities in the BCPP trial and the source of transmission resides in an intervention community.
- 4. The intercept denotes the risk of HIV-1 transmission (i.e. expected probability of viral linkage) in the reference category.
- 5. Coefficients, standard errors and confidence bound values are presented on the linear scale and *p*-values are 2-sided.
- 6. **Transmission source:** *control community* denotes the effect on the risk of HIV-1 transmission when the source of transmission resides in a control community.
- 7. **Transmission type:** *same community* denotes the effect on the risk of HIV-1 transmission when both the source and recipient reside within the same community.
- 8. Drive distance between communities in kilometers denotes the effect on the risk of HIV-1 transmission for a 1 kilometer increase in the drive distance separating a pair of communities.

**Supplementary Table 3:** A comparison of the number of transmission pairs identified in the BCPP trial during the post-baseline period (n = 31) with those expected under the post-baseline model in Table 1. Table 1 describes the risk of HIV-1 transmission between communities.

Pairwise drive distance bin in kilometers	Median of bin	Number of distinct possible transmission pairs in bin	Number of identified trans- mission pairs	Number of expected trans- mission pairs
[0, 50]	25	226,500	19	26
(50, 120]	85	205,621	3	3
(120, 220]	170	209,215	5	3
(220, 320]	270	232,686	0	2
(320, 410]	365	256,466	2	2
(410, 475]	442.5	220,073	0	1
(475, 710]	592.5	197,104	1	1
(710, 915]	812.5	210,298	1	0
(915, 1045]	980	196,782	0	0
(1045, 1200]	1122.5	235,449	0	0

# Notes:

- 1. The pairwise drive distances separating communities in the BCPP trial were grouped into ten bins that each had approximately similar numbers of the maximum number of distinct possible opposite-sex transmission pairs (see Model diagnostics in supplementary appendix section S1.2).
- 2. The expected number of transmission pairs was estimated with the post-baseline model in Table 1.
- 3. There was little evidence to suggest that the observed counts differed substantially from those expected under the post-baseline model in Table 1 (Fisher exact P = 0.792).



Supplementary Figure 1. Distribution of directed opposite-sex transmission pairs identified between ordered pairs of the 30 communities in the BCPP trial. The barplots in panels A and B show distributions of transmission pairs identified during the baseline (blue bars) and post-baseline (green bars) periods of the BCPP trial, respectively. For example, in panel A there were 20 ordered community pairs that each had a single identified opposite-sex transmission pair and 7 ordered community pairs that each had 2 identified transmission pairs. Panels C and D show the corresponding empirical and theoretical cumulative distribution functions (cdf) of identified transmission pairs during the baseline (panel C) and post-baseline (panel D) periods of the BCPP trial. In both panels C and D the empirical distribution is shown in black, and the theoretical Poisson and negative-binomial distributions are illustrated by solid purple lines and orange broken lines, respectively. The positively skewed distributions of identified transmission pairs in the BCPP trial are better approximated with a negative-binomial distribution compared to a Poisson distribution.



Supplementary Figure 2. Spatial distribution of the estimated number of people with HIV-1 in Botswana. Estimates of the number of people with HIV-1 were computed from district HIV-1 prevalence estimates from the 2013 Botswana AIDS Impact Survey (BAIS 2013) and community-size estimates from the 2011 Botswana population and housing census. Intervention communities in the BCPP trial are denoted by purple filled circles and boundaries and control communities are represented by green filled circles and boundaries. The communities in the BCPP trial are distributed around three major urban areas: Gaborone city, Palapye and Francistown city represented by blue filled circles and labels.



50

DHARMa residual

Supplementary Figure 3. A quantile-quantile (QQ) residual plot that compares the distribution of residuals of 31 opposite-sex transmission pairs identified between ordered pairs of communities in the BCPP trial during the post-baseline period with those that would be expected under the post-baseline model in Table 1.



Supplementary Figure 4. A scatter plot that shows a positive correlation between the estimated number of HIV-1 transmissions to recipients in trial communities that were predicted by the post-baseline model in Table 1 in the absence of the intervention and the total possible distinct opposite-sex transmission pairs that involve recipients in trial communities. The maximum (or total) distinct possible opposite-sex transmission pairs that involve recipients in trial communities. The maximum (or total) distinct possible opposite-sex transmission pairs that involve recipients in trial communities represent the opportunity for transmission to recipients in the the trial communities, and are computed from the community size and HIV-1 prevalence of the source community and the number of people with HIV-1 sampled from the recipient community during the post-baseline period when the intervention could have taken effect. The BCPP trial matched communities into 15 pairs based on geographical proximity to major urban areas, population-size and age structure, and access to health services.